Xenia Venture Capital Ltd. (TASE:XENA) portfolio company Nexsig Neurological Examination Technologies Ltd. has raised NIS 4 million from a group of investors led by Kadima Hi-Tech Ltd., Rosenram Business Development Ltd., Altshuler Shaham Ltd. and other investors.
Under the investment agreement, Israeli Association of Medical Information Systems chairman Ami Sadan was appointed chairman of Nexsig, Beilinson Medical Center director Boaz Tadmor, Kadima Hi-Tech managing director Yossi Ben-Yossef, and Rosenram director Revital Aviram were appointed as company directors.
Nexsig has developed software for diagnosing Alzheimer’s disease, which does not require human intervention. The company says that its system measure and analyze in real time biometric signals though self-administered computer tests to give more accurate and earlier diagnoses. The system has been tested on 1,500 persons, and has been sold to Dikla Insurance Co. Ltd. and Macabbi Healthcare Services in Israel, Brigham and Women’s Hospital in Boston, and a geriatric institute in Manchester, UK.
Kadima Hi-Tech and Rosenram have made joint investments in Rosetta Genomics Ltd. (Nasdaq:ROSG), Evogene Ltd. (TASE:EVGN), and BiondVax Pharmaceuticals Ltd. (TASE:BNDX).
Published by Globes [online], Israel business news - www.globes.co.il - on July 22, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007